CytomX Therapeutics Secures Funding for Varseta-M Development
CytomX Therapeutics: Cashed Up With Catalysts Ahead
Image: Seeking Alpha
CytomX Therapeutics (CTMX) raised $234.2 million to support the development of Varseta-M for metastatic colorectal cancer. The company's cash reserves of $346.7 million will fund operations through at least the second half of 2028, with updated data expected in late 2026 and a potential trial start in early 2027.
- 01CTMX showcased Varseta-M's potential for late-line metastatic colorectal cancer in March.
- 02The company raised $234.2 million following a Q1'26 data update, enhancing its cash runway.
- 03CTMX's cash position stands at $346.7 million, supporting operations into at least H2'28.
- 04Increased R&D spending is anticipated as development programs expand.
- 05Updated data from Varseta-M's monotherapy work is expected in H2'26, with a potential registrational trial in H1'27.
Advertisement
In-Article Ad
CytomX Therapeutics (CTMX) raised $234.2 million in funding to advance the development of Varseta-M, a treatment for late-line metastatic colorectal cancer. Despite some toxicity concerns, CTMX's cash reserves of $346.7 million will sustain operations through at least the second half of 2028, allowing for increased research and development spending. The company plans to report updated data from its monotherapy studies in late 2026 and may initiate a registrational trial in early 2027. This funding will enable broader development of Varseta-M, positioning CTMX for potential growth in the oncology market.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
What do you think about CytomX Therapeutics' prospects with Varseta-M?
Connecting to poll...
Read the original article
Visit the source for the complete story.